Table 1.
Women with Breast Cancer |
Women without Breast Cancer |
|||
---|---|---|---|---|
Phenols Sample (n=711) |
Parent Study Sample (n=1,508) |
Phenols Sample (n=598) |
Parent Study Sample (n=1,556) |
|
Age at reference (years) | ||||
<50 | 196 (27.6%) | 407 (27.0%) | 197 (32.9%) | 499 (32.1%) |
50–64 | 259 (36.4%) | 582 (38.6%) | 250 (41.8%) | 617 (39.7%) |
≥65 | 256 (36.0%) | 519 (34.4%) | 151 (25.2%) | 440 (28.3%) |
Income | ||||
<$24,999 | 154 (21.7%) | 286 (19.0%) | 104 (17.4%) | 295 (19.0%) |
$25,000–$49,999 | 227 (32.0%) | 488 (32.4%) | 172 (28.8%) | 475 (30.6%) |
≥$50,000 | 328 (46.3%) | 730 (48.5%) | 321 (53.8%) | 784 (50.5%) |
Missing | 2 | 4 | 1 | 2 |
Education | ||||
<HS/HS graduate | 340 (47.9%) | 721 (48.0%) | 240 (40.2%) | 676 (43.6%) |
College | 261 (36.8%) | 551 (36.7%) | 263 (44.0%) | 651 (41.9%) |
Post-college | 109 (15.3%) | 230 (15.3%) | 94 (15.8%) | 225 (14.5%) |
Missing | 1 | 6 | 1 | 4 |
Menopausal status | ||||
Premenopausal | 226 (32.6%) | 472 (31.9%) | 211 (37.1%) | 503 (33.7%) |
Postmenopausal | 468 (67.4%) | 1,006 (68.1%) | 357 (62.9%) | 990 (66.3%) |
Missing | 17 | 30 | 30 | 63 |
HRT use | ||||
Never | 506 (71.3%) | 1,096 (72.9%) | 439 (73.4%) | 1,159 (74.5%) |
Ever | 204 (28.7%) | 408 (27.1%) | 159 (26.6%) | 396 (25.5%) |
Missing | 1 | 4 | 0 | 1 |
Age at menarche (years) | ||||
≤12 | 311 (44.1%) | 658 (44.0%) | 274 (46.0%) | 677 (43.8%) |
>12 | 394 (55.9%) | 837 (56.0%) | 321 (54.0%) | 870 (56.2%) |
Missing | 6 | 13 | 3 | 9 |
Oral Contraceptive use | ||||
Never | 406 (57.2%) | 848 (56.3%) | 304 (50.8%) | 840 (54.0%) |
Ever | 304 (42.8%) | 657 (43.7%) | 294 (49.2%) | 715 (46.0%) |
Missing | 1 | 3 | 0 | 1 |
Parity/lactation history | ||||
Nulliparous | 92 (12.9%) | 198 (13.1%) | 70 (11.7%) | 171 (11.0%) |
Parous/never lactated | 375 (52.7%) | 830 (55.0%) | 302 (50.5%) | 832 (53.5%) |
Parous/ever lactated | 244 (34.3%) | 480 (31.8%) | 226 (37.8%) | 553 (35.5%) |
Family history of breast cancer | ||||
None | 564 (82.1%) | 1,166 (79.8%) | 498 (84.7%) | 1,321 (87.0%) |
First degree | 123 (17.9%) | 295 (20.2%) | 90 (15.3%) | 197 (13.0%) |
Missing | 24 | 47 | 10 | 38 |
BMI at reference (kg/m2) | ||||
<25.0 | 316 (44.6%) | 683 (45.8%) | 309 (52.2%) | 750 (49.1%) |
25.0-29.9 | 220 (31.0%) | 476 (31.9%) | 160 (27.0%) | 455 (29.8%) |
≥30.0 | 173 (24.4%) | 332 (22.3%) | 123 (20.8%) | 323 (21.1%) |
Missing | 2 | 17 | 6 | 28 |
BMI at age 20 (kg/m2) | ||||
<25.0 | 653 (93.0%) | 1,377 (93.0%) | 534 (90.2%) | 1,397 (91.2%) |
≥25.0 | 49 (7.0%) | 103 (7.0%) | 58 (9.8%) | 135 (8.8%) |
Missing | 9 | 28 | 6 | 24 |
Lifetime alcohol intake (g/day) | ||||
Non-drinkers | 263 (37.0%) | 598 (39.7%) | 225 (37.7%) | 605 (39.0%) |
<15 | 339 (47.7%) | 691 (45.8%) | 289 (48.4%) | 735 (47.3%) |
15-29 | 71 (10.0% | 147 (9.7%) | 48 (8.0%) | 119 (7.7%) |
≥30 | 38 (5.3%) | 72 (4.8%) | 35 (5.3%) | 94 (6.1%) |
Stage | ||||
In situ | 112 (15.8%) | 235 (15.6%) | – | – |
Invasive | 599 (84.2%) | 1,273 (84.4%) | – | – |
Tumor size | ||||
≤2cm | 279 (73.6%) | 622 (75.5%) | – | – |
>2cm | 100 (26.4%) | 202 (24.5%) | – | – |
Missing | 332 | 684 | – | – |
ER status | ||||
Negative | 115 (23.8%) | 264 (26.7%) | – | – |
Positive | 368 (76.2%) | 726 (73.3%) | – | – |
Missing | 228 | 518 | – | – |
Radiation therapy | ||||
No | 192 (38.4%) | 401 (39.1%) | – | – |
Yes | 308 (61.6%) | 625 (60.9%) | – | – |
Missing | 211 | 482 | – | – |
Chemotherapy | ||||
No | 297 (59.6%) | 599 (58.6%) | – | – |
Yes | 201 (40.4%) | 423 (41.4%) | – | – |
Missing | 213 | 486 | – | – |
Hormone therapy | ||||
No | 188 (38.1%) | 393 (39.0%) | – | – |
Yes | 306 (61.9%) | 616 (61.0%) | – | – |
Missing | 217 | 499 | – | – |
Long Island Breast Cancer Study Project (LIBCSP) population-based women without breast cancer were frequency matched by age to women diagnosed with breast cancer between August 1, 1996 and July 31, 1997.